evidence of pathologically confirmed, advanced nsclc (with known histology).

prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced nsclc).

adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.

adequate renal, hematologic, liver function.

ecog ps of 0-2.

radiologically measurable disease.

small cell histology.

symptomatic brain mets or known leptomeningeal mets.

prior therapy with agent known or proposed to be active by action on egfr tyrosine kinase or other her family proteins.

uncontrolled medical disorders.